So you want a classic car? Be warned…
The Aston Martin DB5 left me shaken, not stirred.
Csl
Earnings, payouts resilient despite COVID
Gains evaporated on Friday as banks and CSL fell, sending the ASX to a 0.2pc weekly loss, while early earnings have been resilient despite the pandemic pessimism.
Vaccine hopes face another obstacle
Investors are assuming a vaccine will fix the crisis, but not everyone, especially in the US, may be willing to co-operate.
Records for Domino’s, ASX, JB Hi-Fi
Consumer stocks surged to records despite a 0.8pc slip in the ASX, while results from Qantas and Wesfarmers prompted little share reaction.
Results rally sends ASX to 6-month high
The ASX jumped 0.7pc to its best level since March, as CSL jumped 6.4pc and WiseTech added more than $2bn to its market value.
CSL narrows in on three potential COVID-19 vaccines
While optimistic, CSL says multiple vaccines will be needed to quash the coronavirus pandemic, as its lifted annual profit 9.6pc.
CSL push for vaccine within a year
‘Emergency doses’ of a COVID-19 vaccine could be delivered by the middle of next year after CSL tightened its development timeline.
ASX finishes higher for second straight day
Healthcare sector giant CSL played a big role in lifting the Australian share market after booking higher full year profits and flagging a potential vaccine for coronavirus in mid-2021.
Biotech giant flags mid-2021 virus vaccine
Australian biotechnology giant CSL has flagged manufacturing 100 million doses of a COVID-19 vaccine by mid next year and reported higher full-year earnings.
ASX adds 0.8pc, Wesfarmers, Appen hit highs
CSL and Cochlear did the heavy lifting as the ASX rose 0.8pc, while several household names surged to record highs at the close.
Why investors would cheer a CSL share split
Is it time to split the shares in biotech giant CSL?
CSL in vaccine talks with AstraZeneca
CSL confirms it is in talks with British pharmaceutical giant AstraZeneca about producing its vaccine in Melbourne.
Trump backs CSL virus treatment
Donald Trump has labelled as ‘tremendous’ a plasma therapy for COVID-19 to be jointly trialled by Australia’s CSL.
Dollar dives, ASX keeps focus on Fed
The $A weakened in late trade after all sectors bar real estate finished higher, led by a lift in CSL, as investors looked past a surge in virus cases in Melbourne.
Money Cafe: Earnings season, CSL, early super withdrawal
Listen to the Money Cafe podcast on earnings season, CSL and the early super withdrawal that has beaten all forecasts.
‘Millions of vaccine doses’ coming
Drug-maker CSL will produce millions of doses of Australia’s experimental COVID-19 vaccine as it is being tested to speed up an anticipated rollout.
Earth’s demise is exaggerated
People should not be alarmed about the supposed effects of carbon dioxide emissions.
Earth could become uninhabitable
Carbon dioxide emissions must be reduced.
CSL boosting flu vaccine supply
There has been a strong take-up of the flu vaccine as people seek to bolster their immunity amid the coronavirus pandemic.
CSL joins COVID-19 vaccine bid
Specialty biotechnology company CSL has weighed into the global race to find a coronavirus vaccine.
Morrison is right on technology
Labor’s zero emissions goal jeopardises the economy.
CSL’s next big thing
As CSL’s share price soars, investors are hungry for more growth. A new wonder drug may just have the answer.
The right time for leadership
Coronavirus fallout threatens some of our stronghold industries, but the right leadership will see us survive and thrive again.
All pain, no gain on emissions
It is not possible to reach zero emissions.
Climate faithful disregard facts
Ideological opportunism rules the climate roost.
Bad banks can’t hold back the ASX
CSL is a star performer, but bad banks haven’t stopped the ASX 200 making big gains this calendar year.
Reducing CO2 won’t cut fire risk
Politicians will grasp any opportunity to avoid taking responsibility.
ASX takes weekly wins to 4
It was a choppy local session, despite optimism in trade talks and ECB stimulus, with gold miners and CSL dragging on trade.
Emissions are everyone else’s job
Reality has brought Qantas chief Alan Joyce down to earth.
Paris climate accord is pointless
The Paris climate aggreement is based on false assumptions about the role of carbon dioxide in global warming.
Original URL: https://www.theaustralian.com.au/topics/csl/page/9